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Abstract
Background: Focal adhesion (FA) family genes have been studied as candidate genes for osteoporosis, but the
results of genetic association studies (GASs) are controversial. To clarify these data, a systematic assessment of GASs
for FA genes in osteoporosis was conducted.
Methods: We developed Cumulative Meta-Analysis of GAS-OSTEOporosis (CUMAGAS-OSTEOporosis), a web-based
information system that allows the retrieval, analysis and meta-analysis (for allele contrast, recessive, dominant,
additive and codominant models) of data from GASs on osteoporosis with the capability of update. GASs were
identified by searching the PubMed and HuGE PubLit databases.
Results: Data from 72 studies involving 13 variants of 6 genes were analyzed and catalogued in CUMAGAS-
OSTEOporosis. Twenty-two studies produced significant associations with osteoporosis risk under any genetic
model. All studies were underpowered (<50%). In four studies, the controls deviated from the Hardy-Weinberg
equilibrium. Eight variants were chosen for meta-analysis, and significance was shown for the variants collagen,
type I, a1 (COL1A1) G2046T (all genetic models), COL1A1 G-1997T (allele contrast and dominant model) and integrin
b-chain b3 (ITGB3) T176C (recessive and additive models). In COL1A1 G2046T, subgroup analysis has shown
significant associations for Caucasians, adults, females, males and postmenopausal women. A differential magnitude
of effect in large versus small studies (that is, indication of publication bias) was detected for the variant COL1A1
G2046T.
Conclusion: There is evidence of an implication of FA family genes in osteoporosis. CUMAGAS-OSTEOporosis could
be a useful tool for current genomic epidemiology research in the field of osteoporosis.
Background
Osteoporosis is a common skeletal disease characterized
by generalized reduction in bone mineral density and
microarchitectural deterioration of bone tissue, leading
to impaired skeletal strength and increased susceptibility
to fracture [1]. Genetic factors have long been recog-
nized as playing an important role in osteoporosis [2].
Major efforts are currently underway to identify the
specific genes and allelic variants predisposing patients
to this disease. The identification of genes is achieved by
conducting hypothesis-free, genome-wide association
studies (GWASs) and candidate gene association studies
(GASs) [3]. Candidate genes are typically chosen on the
basis of having biological effects on bone metabolism or
bone cell activity and whether they contribute to the
risk of osteoporosis [3].
The focal adhesion (FA) gene family has emerged as a
logical candidate for osteoporosis. Focal adhesions are
specialized structures at the cellular-extracellular matrix
contact points, where bundles of actin filaments are
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family through a multimolecular complex of junctional
plaque proteins. Some of the constituents of FA genes
participate in the structural link between membrane
receptors and the actin cytoskeleton, while others are
signaling molecules [4,5]. Although there are a number
of genes constituting the pathway, only a small number
of variants of these genes have been studied in GASs of
osteoporosis. More recently, haplotype-based approaches
and genome-wide genotyping platforms have enabled
more comprehensive capture of genetic variation in
these genes [6]. The most studied gene is the collagen,
type I, a1 (COL1A1) gene, especially its variant G2046T.
Other genes studied in the FA family include the genes
insulin-like growth factor I (IGF-I), integrin b-chain b3
(ITGB3), a-actinin-3 (ACTN3), COL1A2 and type 1
insulin-like growth factor receptor (IGF-IR). However,
the results of the GASs involving genes of the FA path-
way and osteoporosis are controversial and inconclusive,
possibly because of methodological limitations, including
inadequate sample size, patient selection, ethnicity of the
populations studied and lack of adjustments for con-
founders [7].
To explore the involvement of FA family gene poly-
morphisms in osteoporosis susceptibility, we systemati-
cally searched for all available GASs of FA family genes
and osteoporosis (as a binary phenotype) and created the
Cumulative Meta-Analysis of Genetic Association Stu-
dies-OSTEOporosis (CUMAGAS-OSTEOporosis) infor-
mation system. Then we catalogued all retrieved articles
and estimated the risk effects of all individually investi-
gated variants. Finally, the available data were synthesized
using meta-analysis techniques to increase the power for
detecting significant results and to decrease the uncer-
tainty of the estimated genetic risks [8].
Methods
Information system
CUMAGAS-OSTEOporosis is a web-based database and
an information system for cumulative meta-analysis of
GASs [[9]; see also [10,11]]. CUMAGAS-OSTEOporosis
performs meta-analysis for all genetic models (allele
contrast, dominant, recessive, additive and codominant)
and provides data on various covariates. Currently,
CUMAGAS-OSTEOporosis operates for binary pheno-
types (that is, osteoporosis: yes or no), but our study
group is expanding the system to analyze continuous
phenotype (bone mineral density).
CUMAGAS-OSTEOporosis is a dynamic system, since
it has the capacity of continuous updating. Authors of
published and unpublished studies may contribute their
data by entering their studies’ data into a prespecified
data entry form (CUMAGAS-FORM) [9]. Furthermore,
authors may correct previously stored data or notify for
missed studies by contacting the CUMAGAS investiga-
tors (cumagas@med.uth.gr).
Selection of Studies
All studies published before June 2010 were identified by
conducting extended computer-based searches of the
PubMed and HuGE PubLit databases. The search criteria
in the PubMed database included a combination of the fol-
lowing terms: Focal adhesion, ACP1, ACTN3, ADRB1,
AKT1, COL1A1, COL1A2, COMP, CREBBP, CSNK1D,
C T N N A 3 ,C T N N B 1 ,D R D 2 ,F G F R 1 ,G R B 2 ,G R B 2 ,I G F - I ,
IGF-IR, ITGA1, ITGA2, ITGA2B, ITGB3, KDR, PARD6A,
PDGFRA, PDGFRB, PIK3CA, PRKACB, PTPN1, SMAD2,
SMAD3, SMAD4, SPP1, TCF7, TGFBR1, TGFBR2, VEGFA,
VWF, osteoporosis, gene, polymorphism, allele and variant.
The bibliographies in the articles that these searches identi-
fied were used to find further references. The HuGE Pub-
Lit database [12] was searched for the disease term
“osteoporosis” and for the gene terms listed above.
The eligible studies fulfilled the following inclusion
criteria: (1) inclusion of cases with clinically diagnosed
osteoporosis and controls free of osteoporosis, (2) infor-
mation provided on genotype frequency or risk esti-
mates (only studies that reported a particular variant
were considered, and missing data were not imputed),
(3) use of DNA-based analytical methods for genotyping
and (4) studies of humans. Studies investigating disease
progression, severity, phenotype modification, response
to treatment or survival were excluded from our study.
Case reports, editorials, review articles and non-English-
language articles were also excluded. Finally, family-
based studies were excluded because of different design
settings. Abstracts of retrieved studies were indepen-
dently read by two investigators (CD and EZ) to assess
their appropriateness for this study. Full-text articles of
the studies were evaluated (by CD and EZ) according to
the inclusion criteria. The results were compared, and
disagreements were resolved by consensus.
Published GWASs of osteoporosis cited in the HuGE
PubLit database [12] and the National Human Genome
Research Institute Catalog of Published Genome-Wide
Association Studies [13] were screened for variants of the
FA gene family. Open access databases for GWASs [14]
were also searched. The variants tested in candidate gene
studies were examined regardless of whether they had
been included or tagged by proxy variants in the genotyp-
ing platforms used in the GWASs of osteoporosis [15].
Data abstraction
From each article, the following information was
extracted: first author, year of publication, ethnicity of
the study population, study design, demographics and
number of cases and controls for each genotype and
effect size. The frequencies of the alleles and the
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both the cases and the controls. The reference single
nucleotide polymorphism identification numbers (rs
numbers), the chromosomal gene position and the
nucleotide base changes for all genetic variants were
identified by performing extended searches of bioinfor-
matics databases [12,14-16].
Data analysis and synthesis
Prior to meta-analysis, the risk effect of gene variants for
the allele contrast and the dominant models were evalu-
ated separately for each study. All associations were indi-
cated as odds ratios (ORs) with the corresponding 95%
confidence intervals (95% CIs). In the meta-analysis, the
heterogeneity between studies was tested using the
Q-statistic [17,18], and it was quantified with the I
2 metric
[8]. Heterogeneity was considered significant when PQ <
0.10 (PQ is the P-value for Q-statistic). The pooled OR was
estimated using the random effects (RE) model [[19]; see
also [8,20]]. The RE model was chosen because it is more
conservative than the alternative fixed effects model,
which does not consider heterogeneity. The differential
magnitude of effect in large versus small studies (that is,
indication of publication bias) was tested using a modified
linear regression test for funnel plot asymmetry proposed
by Harbord et al. [21]. This effect was considered signifi-
cant when the P-value for Harbord’s test was PH<0.05.
The meta-analysis consisted of the main (that is, overall)
analysis, which included all available data, as well as sub-
group analyses by ethnicity, gender, age, menopausal sta-
tus and sensitivity analysis which examined the effect of
excluding specific studies [8,20].
The distribution of each variant in the control group was
tested for the Hardy-Weinberg equilibrium (HWE) [22].
HWE indicates possible genotyping errors and/or popula-
tion stratification [8]. Sensitivity analysis was carried out
for the studies that deviated from HWE and the studies
for which HWE could not be tested (that is, the pooled
OR was calculated after excluding these studies). The
power of each study for the allele contrast was calculated
assuming a 20% alteration in effect size (that is, modest
effect), a significance level of 0.05 and a disease allele
frequency equal to the one of the study population [11].
Analyses were performed using the CUMAGAS-OSTEO-
porosis database [9] and Compaq Visual Fortran 90 soft-
ware (Compaq Computer Corporation, Houston, Texas,
US) with the International Mathematics and Statistics
Library (Visual Nuemerics Inc, Houston, Texas, US).
Results
Eligible articles
The literature review identified 169 titles in the PubMed
and HuGELit databases that met the search criteria. The
search in HuGE PubLit and the databases for GWASs
traced articles already identified by PubMed. After
abstract selection, 132 articles remained. When an arti-
cle provided data for different populations, then each
population was considered as a different study [23-27].
Thirty-nine articles consisting of 72 studies that investi-
gated the association between genetic variants of the FA
family genes and osteoporosis fulfilled the inclusion cri-
teria. Figure 1 presents a flowchart of retrieved studies
and studies that were excluded, with specification of the
reasons for inclusion or exclusion (a list of the excluded
studies is provided in Additional file 1). Overall, 6 genes
and 13 distinct variants of these genes investigated in
the 72 gene-disease association studies were identified.
The studies were published between 1996 and 2010.
Studies’ characteristics and association results
The characteristics of each study and the association
results of variants are shown in Additional file 2. In
GWASs, none of the variants of the FA gene family
were reported as significant, nor were the variants
examined in the meta-analyses captured by the genotyp-
ing platforms used in the GWASs [28,29].
Studies were conducted in various populations of dif-
ferent racial descent: Sixty-six studies involved solely
Caucasians, two studies recruited East Asians, three
169 articles were found in PUBMED 
12 articles were not in humans 
7 articles were non-English 
132 potentially relevant 
articles based on abstracts 
18 non-relevant articles 
88 articles investigating 
the association FA genes 
and osteoporosis 
12 articles investigated gene expression
11 articles were reviews 
10 articles were family- based studies  
3 articles were case reports 
7 articles were meta-analyses  
1 article as a comment on a previous article 
39 articles included in 
the synopsis 
45 studies investigated the bone mineral 
density or had lack of control group
2 studies were using overlapping samples 
4 studies did not provide genotype 
distribution or other risk estimates 
2 studies were traced from references 
Figure 1 Flowchart of retrieved studies and studies excluded,
with specification of reasons.
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tion of Mexican origin. Twenty-three studies involved
only postmenopausal women. Twelve studies provided
data for men and women. One study involved children.
The distribution of genotypes in the control group
deviated from HWE in 4 studies, and in 20 studies the
HWE deviation could not be tested. In all studies, the
statistical power for detecting a significant risk effect
was lower than 50%. In total, 22 studies produced signif-
icant associations with osteoporosis risk under any
genetic model. The significant associations concerned
the variants COL1A1 G2046T, COL1A1 RsaIi n t r o n5 ,
COL1A2 PvuII and ITGB3 T176C.
Meta-analysis results
In total, eight variants were investigated in two or more
studies, and their results were meta-analyzed: COL1A1
G2046T (Sp1 SS/ss, rs1800012), COL1A1 G-1997T
(rs1107946), COL1A1 -1663T ins/del (rs2412298), COL1A1
MspI 26 kb upstream, COL1A1 RsaIi n t r o n5 ,COL1A1
MnII exon 52, IGF-I 192 bp CA and ITGB3 T176C
(rs5920). Table 1 shows the meta-analysis results for the
association between the different variants and the risk of
developing osteoporosis. Significant results are shown for
the variants COL1A1 G2046T, COL1A1 G-1997T and
ITGB3 T176C. Additional file 3 shows the associations of
the individual studies and the meta-analysis results for the
dominant model of the variant COL1A1 G2046T.
In particular, there was a significant overall association
for the allele contrast of the variant COL1A1 G2046T
(OR, 1.65; 95% CI, 1.39-1.94) with the heterogeneity
between studies being significant (I
2 =6 9 % ;PQ < 0.01).
In subgroup analysis, a significant association was
shown for Caucasians (OR, 1.60; 95% CI, 1.36-1.88),
adults (OR, 1.48; 95% CI, 1.29-1.70), females (OR, 1.37;
95% CI, 1.20-1.57), males (OR, 1.85; 95% CI, 1.09-3.14)
and postmenopausal women (OR, 1.34; 95% CI, 1.14-
1.58). The recessive, dominant, additive and codominant
models produced similar results (with the exception of
subgroup analysis for males for the recessive and addi-
tive models). The sensitivity analysis for HWE did not
alter the pattern of results.
Significant results were also shown for the variants
COL1A1 G-1997T (allele contrast and dominant model)
and ITGB3 T176C (recessive and additive models). How-
ever, these results were based on a small number of stu-
dies, and therefore safe conclusions could not be drawn.
In the overall meta-analyses for the allele contrast, a differ-
ential magnitude of effect in large versus small studies was
detected only for the variant COL1A1 G2046T (PH = 0.01).
Discussion
In this project, the currently available data from GASs
on human FA family genes in osteoporosis were
catalogued. Then the data were synthesized, and the
involvement of FA gene variants in disease susceptibility
was assessed comprehensively. The eligible GASs were
catalogued in a publicly available web-based database
and information system called CUMAGAS-OSTEO-
porosis [9]. In total, eight variants were meta-analyzed.
Significant results were shown for the variants COL1A1
G2046T, COL1A1 G-1997T and ITGB3 T176C. Type I
collagen is the major protein constituent of bone and is
therefore a strong and plausible candidate gene for
osteoporosis. The COL1A1 G2046T polymorphism is a
single base pair substitution (G ® T) within the regula-
tory region of the COL1A1 gene [30]. The COL1A1
G-1997T polymorphism has been identified in the prox-
imal promoter of COL1A1 at position -1997 and is in
linkage disequilibrium with the COL1A1 G2046T poly-
morphism [31]. There is evidence that the promoter
polymorphisms are functional and have effects on DNA
binding and gene transcription [32], but it is unclear to
what extent this polymorphism is associated with the
biomechanical properties of bone or susceptibility to
fracture. Taking into consideration the abundance of
COL1A1 in the bones and the fact that these variants
seem to play a major role in the function of the gene,
the significant association found in our results may
encourage intensive research in this area. The ITGB3
T176C polymorphism changes the conformational struc-
ture of the b3-subunit of integrin [33]. The integrin
b3-subunit is known to play a key role in the resorptive
function of osteoclasts, as shown in vitro and in trans-
genic animal studies [34]. Genetic variation in integrin
b3 may influence bone remodeling and subsequent bone
loss and risk of osteoporotic fractures.
CUMAGAS-OSTEOporosis is an evidence-based
information system for systematically searching, review-
ing and synthesizing data for GASs of osteoporosis, with
the capacity for continuous updating. CUMAGAS is
being expanded to additional complex diseases such
chronic lymphocytic leukemia, peripheral arterial dis-
ease, hypertension and osteoarthritis [10,9,35,36].
CUMAGAS also has the capacity to incorporate data
from GWASs subject to their public availability.
T h eG W A S so fo s t e o p o r o s i sh a v en o th i g h l i g h t e da
significant role for the FA family of genes. However, the
commercial genotyping platforms [15] may underrepre-
sent the variants of the FA pathway and, of course, the
variants included in the meta-analysis. In addition, the
variants identified to date from the GWAS approach
explain only a fraction of the disease heritability, and
therefore the potential role for the variants of FA path-
way may not be excluded [36]. Furthermore, the ana-
lyses of GWASs have missed associations of multilocus
variants involved in pathways with pathophysiological
relevance to disease mechanisms [3,36].
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2)
and significance of the differential magnitude of effect in large versus small studies (PH) for allele contrast and
dominant and recessive models
a
Gene Study type Population Studies (n) Cases/Controls (n) OR (95% CI) I
2 (%) (PQ value) PH
COL1A1 G2046T Allele contrast All 33 7,308/10,128 1.65 (1.39-1.94) 69 (<0.01) 0.01
All in HWE 31 6,660/8,968 1.68 (1.41-2.01) 70 (<0.01) 0.01
Caucasians 28 6,896/9,645 1.47 (1.29-1.68) 50 (<0.01) <0.01
Adults 32 7,234/9,944 1.54 (1.33-1.78) 57 (<0.01) 0.01
Female 21 5,942/8,104 1.37 (1.20-1.57) 40 (0.03) 0.05
Postmenopausal 14 4,185/5,722 1.34 (1.14-1.58) 41 (0.06) 0.53
Male 5 706/1,298 1.85 (1.09-3.14) 55 (0.06) 0.81
Recessive model All 33 3,661/5,071 2.37 (1.78-3.16) 16 (0.21) 0.26
All in HWE 31 3,337/4,491 2.37 (1.73-3.25) 20 (0.16) 0.16
Caucasians 28 3,592/5,021 2.29 (1.76-3.00) 2 (0.43) 0.08
Adults 32 3,661/5,071 2.24 (1.75-2.88) 0 (0.48) 0.18
Female 21 3,300/4,373 2.00 (1.52-2.63) 0 (0.54) 0.65
Postmenopausal 14 2,496/3,261 1.80 (1.29-2.50) 2 (0.43) 0.85
Male 5 757/1,049 5.47 (2.31-12.95) 0 (0.57) 0.11
Dominant model All 35 3,928/5,346 1.60 (1.34-1.91) 64 (<0.01) 0.01
All in HWE 31 3,331/4,485 1.67 (1.37-2.03) 65 (<0.01) 0.03
Caucasians 30 3,722/5,104 1.43 (1.23-1.65) 46 (<0.01) <0.01
Adults 34 3,891/5,254 1.53 (1.30-1.81) 58 (<0.01) 0.02
Female 23 3,245/4,334 1.37 (1.18-1.58) 36 (0.05) 0.02
Postmenopausal 15 2,311/3,013 1.33 (1.12-1.58) 33 (0.10) 0.41
Male 5 354/650 1.54 (0.81-2.93) 54 (0.07) 0.98
Additive model All 33 2,487/3,658 2.64 (1.93-3.60) 24 (0.11) 0.13
All in HWE 31 2,267/3,275 2.68 (1.90-3.78) 28 (0.08) 0.07
Caucasians 28 2,447/3,626 2.46 (1.86-3.26) 9 (0.33) 0.03
Adults 32 2,487/3,658 2.57 (1.94-3.41) 11 (0.29) 0.03
Female 21 2,242/3,159 2.14 (1.59-2.89) 8 (0.35) 0.31
Postmenopausal 14 1,694/2,399 1.94 (1.31-2.86) 20 (0.24) 0.55
Male 5 547/843 5.18 (2.16-12.42) 0 (0.58) 0.20
Codominant All 49 9,722/22,924 1.17 (1.04-1.31) 69 (<0.01) 0.13
All in HWE 31 3,331/4,485 1.33 (1.11-1.60) 57 (<0.01) 0.31
Caucasians 44 9,516/22,682 1.12 (1.01-1.26) 68 (<0.01) 0.14
Adults 48 9,685/22,832 1.17 (1.04-1.31) 69 (<0.01) 0.13
Female 30 7,497/16,464 1.12 (0.99-1.26) 62 (<0.01) 0.38
Postmenopausal 15 3,290/6,530 1.16 (0.98-1.37) 36 (0.08) 0.26
Male 12 1,896/6,098 1.07 (0.80-1.44) 78 (<0.01) 0.29
COL1A1 G-1997T Allele contrast All 3 778/852 1.38 (1.05-1.81) 0 (0.94) 0.11
Recessive model All 3 389/426 1.66 (0.67-4.11) 0 (0.70) 0.95
Dominant model All 3 389/426 1.42 (1.04-1.93) 0 (0.88) 0.53
Additive model All 3 279/330 1.08 (0.72-4.49) 0 (0.73) 0.93
Codominant All 3 389/426 1.36 (0.99-1.87) 0 (0.73) 0.71
COL1A1 -1663T ins/del Allele contrast All 3 776/850 1.03 (0.81-1.33) 0 (0.73) 0.14
Recessive model All 3 388/425 1.81 (0.87-3.71) 0 (0.78) 0.11
Dominant model All 3 388/425 0.94 (0.70-1.26) 0 (0.49) 0.09
Additive model All 3 283/295 1.74 (0.84-3.58) 0 (0.86) 0.20
Codominant All 3 388/425 0.82 (0.58-1.15) 12 (0.32) 0.06
COL1A1 MspI2 6k b
upstream (mt
-/wt
+)
Allele contrast All 2 318/312 1.33 (0.95-1.86) NA (0.86) NA
Recessive model All 2 159/156 1.44 (0.69-2.98) NA (0.51) NA
Dominant model All 2 159/156 1.43 (0.91-2.23) NA (0.92) NA
Additive model All 2 88/94 1.66 (0.78-3.56) NA (0.50) NA
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detecting the minor contribution of common alleles. For
example, a sample size of more than 10,000 patients is
needed to achieve >80% power to detect a significant
OR between 1.1 and 1.5 (modest effect) for a poly-
morphic locus in association with a complex disease
[37]. Meta-analysis is a tool that allows for analysis with
the potential for higher power by pooling the results of
multiple studies [8]. However, there is no formal,
established methodology for calculating the power of a
meta-analysis. In addition, power analysis may not be
applicable in meta-analysis, since it is a retrospective, all-
inclusive synthesis of published studies [8,38]. Neverthe-
l e s s ,t y p eI Ie r r o r sa r ee x p e c t e dt ob el e s sc o m m o ni na
meta-analysis than in single studies [8,39]. Currently, no
single institution alone is able to provide a sufficient
number of patients, and therefore the creation of large
databases from consortia where researchers share their
data are required. However, this need for data sharing
has been pointed out by previous initiatives [40,41].
Two problems in human genome epidemiology
research are that negative studies are frequently unpub-
lished and some studies do not provide extractable data,
which lead to the well-known phenomenon of publica-
tion bias [42]. However, negative results should also
have a venue for publication. Moreover, the inclusion of
“negative” and unpublished data in meta-analyses of
GASs as a means of reducing publication bias is com-
monly suggested and is believed to help in pointing out
genetic effects [43]. Thus, the establishment of an
electronic information system to aid in performing
cumulative meta-analyses of (published and unpub-
lished) GASs of osteoporosis and identifying significant
genetic variants could be a valuable tool for ongoing
research in the field. Furthermore, CUMAGAS-OSTEO-
porosis will support rapid progress in human genome
epidemiology of osteoporosis by identifying valid and
replicable associations and making the overall effect of
each variant from published and unpublished studies
rapidly available to researchers. Concerning the retrieval
of unpublished studies, the authors of unpublished stu-
dies will be able to submit their data to the CUMA-
GAS-OSTEOporosis database. Since these data will not
have undergone peer review, a sensitivity analysis may
be carried out (that is, a meta-analysis that examines the
effect of excluding these studies). Finally, CUMAGAS-
OSTEOporosis is an open access system, and it may
support efforts to prevent publication bias [44].
Publication bias was tested using the method proposed
by Harbord et al. [21], which is a modification of Egger’s
test [45], and it is appropriate for small-study effects.
The visual inspection of funnel plots was avoided, since
their validity is questionable [46,47]. However, the statis-
tical tests used to evaluate studies for publication bias
actually compare the differential magnitude of effects in
large versus small studies [8,48].
The significance of risk effects in the GASs was
assessed using the OR metric for various genetic models
(dominant, recessive, additive and codominant) by mer-
ging genotypes. These models are not independent, and
Table 1 Meta-analysis results, odds ratios with corresponding 95% confidence intervals, heterogeneity metrics (PQ, I
2)
and significance of the differential magnitude of effect in large versus small studies (PH) for allele contrast and domi-
nant and recessive models
a (Continued)
Codominant All 2 159/156 1.25 (0.79-1.97) NA (0.87) NA
COL1A1 RsaI intron 5 (mt
-/wt
+) Allele contrast All 2 318/312 1.03 (0.37-2.91) NA (0.01) NA
Recessive model All 2 159/156 0.85 (0.27-2.66) NA (0.47) NA
Dominant model All 2 159/156 1.09 (0.29-4.19) NA (<0.01) NA
Additive model All 2 96/103 0.90 (0.23-3.42) NA (0.25) NA
Codominant All 2 159/156 1.13 (0.33-3.89) NA (0.01) NA
COL1A1 MnII exon 52 (mt
-/wt
+) Allele contrast All 2 318/312 0.77 (0.55-1.07) NA (0.41) NA
Recessive model All 2 159/156 0.70 (0.18-2.75) NA (0.07) NA
Dominant model All 2 159/156 0.78 (0.50-1.22) NA (0.84) NA
Additive model All 2 96/93 0.63 (0.20-2.00) NA (0.14) NA
Codominant All 2 159/156 0.95 (0.47-1.93) NA (0.12) NA
IGF-I 192 bp CA (mt
-/wt
+) Dominant model All 2 47/136 0.70 (0.15-3.35) NA (0.03) NA
ITGB3 T176C Allele contrast All 2 534/17,932 1.23 (0.87-1.76) NA (0.11) NA
Recessive model All 2 267/8,966 1.88 (1.06-3.33) NA (0.76) NA
Dominant model All 2 267/8,966 1.20 (0.76-1.90) NA (0.09) NA
Additive model All 2 192/6,517 1.93 (1.09-3.45) NA (0.58) NA
Codominant All 2 267/8,966 1.09 (0.68-1.72) NA (0.10) NA
aOR, odds ratio; 95% CI, 95% confidence interval; I
2, quantification of heterogeneity; PQ, P-value for heterogeneity; PH, P-value for magnitude of effect in large
versus small studies; COL1A1, collagen, type I, a1; NA, not applicable; HWE, Hardy-Weinberg equilibrium; mt, mutant type; wt, wild type; IGF-I, insulin-like growth
factor I; ITGB3, integrin b-chain b3.
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choice. Consequently, the interpretation of the results
can be problematic, especially when all genetic contrasts
are significant as in the case of COL1A1 G2046T. In
these cases, the introduction of the recently proposed
generalized OR (ORG) as an overall genetic risk effect
m a yb ear e m e d y[ 4 2 ] .T h eO R G is a single statistic that
summarizes the magnitude and significance of the asso-
ciation without considering the hash of possible con-
trasts, and thus the interpretation of the results is
straightforward [49]. The meta-analysis methodology in
CUMAGAS-OSTEOporosis is expanding to incorporate
the ORG metric and the continuous phenotype of osteo-
porosis (that is, bone mineral density).
In the meta-analysis, various genetic contrasts in differ-
ent populations were explored, since there is no biologi-
cal justification for choosing a specific contrast [49].
Thus, adjustment for multiple testing is not strictly
required for such an exploratory study [8,50]. In addition,
the adjustment for multiple testing might not be neces-
sary, since the data were synthesized with the objective of
reducing the uncertainty of effect size, without a prespe-
cified hypothesis [50-52]. Furthermore, an appropriate
multiple test adjustment might be difficult because the
investigated contrasts are not independent and there is
no clear structure in the multiple tests [49,52]. Finally, an
adjustment for multiple comparisons (for example, Bon-
ferroni’s correction) concerns a general null hypothesis
that there is no association in all genetic contrasts simul-
taneously, which is not likely [53,54].
The phenotypic heterogeneity of osteoporosis in the
included studies in our synopsis makes the effort to com-
bine the findings of GASs meaningfully in the complex
field of osteoporosis a difficult task. Thus, in the presence
of the large heterogeneity, the results should be inter-
preted with caution. There may be fundamental differ-
ences in the nature of genetic susceptibility to
osteoporosis between postmenopausal and premenopausal
women and between the two sexes or even among patients
of different ethnicities. Furthermore, environmental fac-
tors, particularly nutrients, have to be accurately evaluated
together with complex genotyping, to weigh their impor-
tance in revealing functional variants with respect to speci-
fic genetic background [55,56]. Our analysis used the
available study-level allele and genotype distributions, pre-
cluding adjusted analysis for potential gene-gene and
gene-environment interactions, for which raw genotype
data would be required. Failure to account for interactions
may have reduced the power of our analysis but is unlikely
to have inflated the number of positive results.
Conclusion
There is evidence implicating the activity of the FA family of
genes in osteoporosis. Future studies designed to investigate
epistatic and gene-environment interactions may help in
deriving more conclusive claims about the role of these
genes in osteoporosis. The CUMAGAS-OSTEOporosis
information system can be a useful resource for reviewing
and interpreting the findings of the accumulating genomic
epidemiologic research in osteoporosis.
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